País: Estados Unidos
Língua: inglês
Origem: NLM (National Library of Medicine)
ANTIHEMOPHILIC FACTOR, HUMAN RECOMBINANT (UNII: P89DR4NY54) (ANTIHEMOPHILIC FACTOR, HUMAN RECOMBINANT - UNII:P89DR4NY54)
Takeda Pharmaceuticals America, Inc.
ANTIHEMOPHILIC FACTOR, HUMAN RECOMBINANT
ANTIHEMOPHILIC FACTOR, HUMAN RECOMBINANT 125 [iU] in 1 mL
ADVATE [Antihemophilic Factor (Recombinant)] is a recombinant antihemophilic factor indicated for use in children and adults with hemophilia A (congenital factor VIII deficiency) for: - Control and prevention of bleeding episodes. - Perioperative management. - Routine prophylaxis to prevent or reduce the frequency of bleeding episodes. ADVATE is not indicated for the treatment of von Willebrand disease. ADVATE is contraindicated in patients who have life-threatening hypersensitivity reactions, including anaphylaxis, to mouse or hamster protein or other constituents of the product (mannitol, trehalose, sodium chloride, histidine, Tris, calcium chloride, polysorbate 80, and/or glutathione). Risk Summary There are no data with ADVATE use in pregnant women to inform a drug-associated risk. Animal reproduction studies have not been conducted with ADVATE. It is not known whether ADVATE can cause fetal harm when administered to a pregnant woman or whether it can affect reproductive capacity. In the U.S. general popu
How Supplied ADVATE in a BAXJECT III system is packaged with 2 mL or 5 mL of Sterile Water for Injection, one Terumo Microbore Infusion set (2 mL only), one full prescribing physician insert, and one patient insert. ADVATE is available in single-dose vials that contain the following nominal product strengths: Actual factor VIII activity in International Units is stated on the label of each ADVATE housing or carton. Not made with natural rubber latex. Storage and Handling
Biologic Licensing Application
ADVATE- ANTIHEMOPHILIC FACTOR (RECOMBINANT) TAKEDA PHARMACEUTICALS AMERICA, INC. ---------- HIGHLIGHTS OF PRESCRIBING INFORMATION THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE ADVATE SAFELY AND EFFECTIVELY. SEE FULL PRESCRIBING INFORMATION FOR ADVATE. ADVATE [ANTIHEMOPHILIC FACTOR (RECOMBINANT)] LYOPHILIZED POWDER FOR RECONSTITUTION, FOR INTRAVENOUS INJECTION INITIAL U.S. APPROVAL: 2003 INDICATIONS AND USAGE ADVATE is a recombinant antihemophilic factor indicated for use in children and adults with hemophilia A for: Control and prevention of bleeding episodes. Perioperative management. Routine prophylaxis to prevent or reduce the frequency of bleeding episodes. ADVATE is not indicated for the treatment of von Willebrand disease. (1) DOSAGE AND ADMINISTRATION FOR INTRAVENOUS INJECTION AFTER RECONSTITUTION ONLY. (2) Each vial of ADVATE contains the labeled amount of recombinant factor VIII in International Units (IU). (2.1) Control and Prevention of Bleeding Episodes and Perioperative Management (2.1) Dose (IU) = body weight (kg) × desired factor VIII rise (IU/dL or % of normal) × 0.5 (IU/kg per IU/dL). Determine treatment frequency based on type of bleeding episode. Routine Prophylaxis (2.1) 20 to 40 IU per kg every other day (3 to 4 times weekly). Alternatively, use every third day dosing regimen targeted to maintain FVIII trough levels ≥1%. DOSAGE FORMS AND STRENGTHS ADVATE is available as a lyophilized powder in single-use vials containing nominally 250, 500, 1000, 1500, 2000, 3000 or 4000 IU. (3) CONTRAINDICATIONS Do not use in patients who have life-threatening hypersensitivity reactions, including anaphylaxis, to mouse or hamster protein or other constituents of the product (mannitol, trehalose, sodium chloride, histidine, Tris, calcium chloride, polysorbate 80, and/or glutathione). (4) WARNINGS AND PRECAUTIONS Hypersensitivity reactions, including anaphylaxis, may occur. Patients may develop hypersensitivity to mouse or hamster protein, which is present in trace amounts in the produc Leia o documento completo